Skip to main content
. 2024 Sep 27;59(12):1744–1753. doi: 10.1038/s41409-024-02422-z

Fig. 3. Cumulative incidence of BOS by cGvHD within the first year after allo-HCT.

Fig. 3

We performed a landmark analysis of cGvHD excluding BOS as risk factor for BOS development. Patients surviving 365 days after allo-HCT were included in the analysis (n = 195). Cumulative incidence of BOS was analyzed by cGvHD onset within the first year after allo-HCT. SHR subdistribution hazard risk, CI confidence interval, cGvHD chronic GvHD, allo-HCT allogeneic hematopoietic cell transplantation.